Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down – Here’s Why

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $13.18, but opened at $12.89. Y-mAbs Therapeutics shares last traded at $12.32, with a volume of 25,075 shares traded.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on YMAB shares. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Morgan Stanley lowered their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. BMO Capital Markets lowered their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Performance

The stock has a market capitalization of $538.81 million, a P/E ratio of -22.50 and a beta of 0.68. The firm’s fifty day simple moving average is $14.08 and its 200 day simple moving average is $13.13.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same period in the prior year, the business earned ($0.18) earnings per share. Analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock worth $1,338,100 in the last ninety days. Company insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its holdings in shares of Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after buying an additional 74,452 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at about $178,000. Millennium Management LLC increased its position in shares of Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after buying an additional 67,233 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in shares of Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares during the period. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.